This is a really helpful graphic summary of the Andes virus outbreak.
#IDSky
We looked at empiric B-lactam antibiotics in MRSA bacteraemia and BC persistence and AKI, using CAMERA2 dataset.
Groups: none, early (only empiric B-lactam), late (only after trial enrolment), throughout (empiric and after enrolment).
#IDSky
www.clinicalmicrobiologyandinfection.org/article/S119...
ESCMID 2026 highlights
Dalbavancin PK (DOTS‑PK) – Two doses may not be enough
High protein binding and wide inter‑patient variability: 1/3 patients may be sub‑therapeutic by day 22
Bottom line: Consider monitoring levels or adding a third dose in complex infections
clarityinitiative.org/home
ESCMID 2026 highlights
COBRA Trial – One day is enough
Dutch RCT: 1 day of antibiotics after ERCP drainage for cholangitis was non‑inferior to 4–7 days.
Bottom line: Antibiotic durations can safely be much shorter once source control is achieved.
#IDSky
clarityinitiative.org/escmid-2026-...
So good. Have spent years fighting this fight, with hand tied behind my back by lack of great evidence.
This study is going to get quoted and cited in microbiology MDTs the world over +++
#IDSky #ClinMicro #AMR
Highlights from ESCMID Global 2026?
@gurujosh.bsky.social asked CLARITY faculty: @angelahuttner.bsky.social @erinmccreary.bsky.social @marcbonten.bsky.social @seanong.bsky.social @ashabowen.bsky.social and others (not on BlueSky).
#IDSky
clarityinitiative.org/escmid-2026-...
Any that we missed?
Our collaboration episode with Breakpoints covering the trials from the ESCMID Global session 'The trial run' is out now! share.transistor.fm/s/e2a9aee4 🎙️✨
@erinmccreary.bsky.social @gurujosh.bsky.social @jesusrbano.bsky.social #IDSky #clinmicro
Clinical Literature Appraisal and Research education in InfecTious diseases
Honored to contribute to this peer-reviewed commentary in CMI Communications alongside an incredible panel of ID physicians and clinical trialists discussing some of the top infectious diseases papers of 2025. #idsky
www.cmi-comms.org/article/S295...
Long awaited!
🆕💥🟢REMAP-CAP
For critically and noncritically ill hospitalized patients with COVID-19, ivermectin was unlikely to improve the primary composite outcome of organ support-free days and hospital survival #idsky
journals.lww.com/ccmjournal/f...
Clinical Literature Appraisal and Research education in InfecTious diseases
clarityinitiative.org
Time for societies to incorporate humility of uncertainty into guidelines
Evidence Over Eminence: Rethinking Specialty Guidelines Amid the ATS-IDSA Debate academic.oup.com/cid/article/...
Steven Tong
Steven Tong
Steven Tong
Steven Tong
In this collaborative episode of Breakpoints and Communicable, the hosts revisit the “trial run” session from ESCMID Global, a format designed to facilitate critical discussion of major infectious dis...
The Society of Infectious Diseases Pharmacists and ESCMID are excited to release a new Breakpoints episode:
ESCMID Global Trials: PETER PEN and ASTARTE
Check it out!
Society of Infectious Diseases Pharmacists - SIDP
ESCMID 2026 highlights
COBRA Trial – One day is enough
Dutch RCT: 1 day of antibiotics after ERCP drainage for cholangitis was non‑inferior to 4–7 days.
Bottom line: Antibiotic durations can safely be much shorter once source control is achieved.
#IDSky
clarityinitiative.org/escmid-2026-...
Clinical Literature Appraisal and Research education in InfecTious diseases
between June 11, 2021, and September 9, 2022.
Patients:
Critically and noncritically ill patients.
Interventions:
Randomized to ivermectin or no ivermectin (control).
Measurements and Main Resu...
Version 9.
New Canadian case (seen one link saying moved to hospital 14th, so presumably onset date), confirmed 14th.
Fixed "2">>"3" April for Case 1.
We're past the 42nd day - 6-week - of incubation since Case 1 onset. Can be as long as 8-weeks in a small percentage. Still all boat-related
Ian M. Mackay, PhD (he/him) 🦠🤧🧬📑🦟🧀
Clarity Initiative offers clinical literature appraisal and research education in infectious diseases, enhancing knowledge through courses and resources.
